Abstract
Background: There are very few clinical or prognostic studies on the role of SRT (Stereotactic Radiation Therapy) in the continuum of care of metastatic colorectal cancer (mCRC) patients. Patients and methods: Patients affected by oligo-mCRC were treated with SRT before or after front-line standard treatments. SRT was delivered according to a risk-adapted protocol. Total body CT (Computed Tomography) scan was done before therapy and every three months thereafter. The radiologic responses to therapy were evaluated by RECIST (Response Evaluation Criteria In Solid Tumors). FDG-PET (FluoroDeoxyGlucose - Positron Emission Tomography) was done before and after SRT; metabolic responses were evaluated by using the EORTC (European Organization for Research and Treatment of Cancer) criteria. The Kaplan-Meier product limit method was applied to graph Overall Survival (OS) and Progression-Free Survival (PFS). Results: Forty-seven patients were included. Twenty-one patients had disease limited to lungs, 9 to lung and liver, 7 only to liver, 10 to multiple sites. The median prescription SRT dose was 60 Gy per organ in 3 fractions (median biological effective dose of 180 Gy). The reduction of delta SUVmax (maximum Standardized Uptake Value) correlated with the local control (p<0.001) and two-years survival (p=0.003). At univariate analysis, localization of primary tumor, site of metastases, KRAS (Kirsten RAt Sarcoma) oncogene mutational status, response to first-line chemotherapy, response to SRT and number of treated lesions predicted both PFS and OS. Discussion: This real practice experience suggests that further studies are needed to analyze the promising role of SRT in the multidisciplinary management of mCRC.
| Original language | English |
|---|---|
| Pages (from-to) | 35251-35265 |
| Number of pages | 15 |
| Journal | Oncotarget |
| Volume | 9 |
| Issue number | 81 |
| Publication status | Published - Oct 1 2018 |
Fingerprint
Keywords
- Chemotherapy
- Colorectal cancer
- Metastatic colorectal cancer
- Radiation therapy
ASJC Scopus subject areas
- Oncology
Cite this
Integration of stereotactic radiotherapy in the treatment of metastatic colorectal cancer patients : A real practice study with long-term outcome and prognostic factors. / Ottaiano, Alessandro; Scotti, Valerio; De Divitiis, Chiara; Capozzi, Monica; Romano, Carmen; Cassata, Antonino; Casaretti, Rossana; Silvestro, Lucrezia; Nappi, Anna; Vicario, Valeria; De Stefano, Alfonso; Tafuto, Salvatore; Berretta, Massimiliano; Nasti, Guglielmo; Avallone, Antonio.
In: Oncotarget, Vol. 9, No. 81, 01.10.2018, p. 35251-35265.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Integration of stereotactic radiotherapy in the treatment of metastatic colorectal cancer patients
T2 - A real practice study with long-term outcome and prognostic factors
AU - Ottaiano, Alessandro
AU - Scotti, Valerio
AU - De Divitiis, Chiara
AU - Capozzi, Monica
AU - Romano, Carmen
AU - Cassata, Antonino
AU - Casaretti, Rossana
AU - Silvestro, Lucrezia
AU - Nappi, Anna
AU - Vicario, Valeria
AU - De Stefano, Alfonso
AU - Tafuto, Salvatore
AU - Berretta, Massimiliano
AU - Nasti, Guglielmo
AU - Avallone, Antonio
PY - 2018/10/1
Y1 - 2018/10/1
N2 - Background: There are very few clinical or prognostic studies on the role of SRT (Stereotactic Radiation Therapy) in the continuum of care of metastatic colorectal cancer (mCRC) patients. Patients and methods: Patients affected by oligo-mCRC were treated with SRT before or after front-line standard treatments. SRT was delivered according to a risk-adapted protocol. Total body CT (Computed Tomography) scan was done before therapy and every three months thereafter. The radiologic responses to therapy were evaluated by RECIST (Response Evaluation Criteria In Solid Tumors). FDG-PET (FluoroDeoxyGlucose - Positron Emission Tomography) was done before and after SRT; metabolic responses were evaluated by using the EORTC (European Organization for Research and Treatment of Cancer) criteria. The Kaplan-Meier product limit method was applied to graph Overall Survival (OS) and Progression-Free Survival (PFS). Results: Forty-seven patients were included. Twenty-one patients had disease limited to lungs, 9 to lung and liver, 7 only to liver, 10 to multiple sites. The median prescription SRT dose was 60 Gy per organ in 3 fractions (median biological effective dose of 180 Gy). The reduction of delta SUVmax (maximum Standardized Uptake Value) correlated with the local control (p<0.001) and two-years survival (p=0.003). At univariate analysis, localization of primary tumor, site of metastases, KRAS (Kirsten RAt Sarcoma) oncogene mutational status, response to first-line chemotherapy, response to SRT and number of treated lesions predicted both PFS and OS. Discussion: This real practice experience suggests that further studies are needed to analyze the promising role of SRT in the multidisciplinary management of mCRC.
AB - Background: There are very few clinical or prognostic studies on the role of SRT (Stereotactic Radiation Therapy) in the continuum of care of metastatic colorectal cancer (mCRC) patients. Patients and methods: Patients affected by oligo-mCRC were treated with SRT before or after front-line standard treatments. SRT was delivered according to a risk-adapted protocol. Total body CT (Computed Tomography) scan was done before therapy and every three months thereafter. The radiologic responses to therapy were evaluated by RECIST (Response Evaluation Criteria In Solid Tumors). FDG-PET (FluoroDeoxyGlucose - Positron Emission Tomography) was done before and after SRT; metabolic responses were evaluated by using the EORTC (European Organization for Research and Treatment of Cancer) criteria. The Kaplan-Meier product limit method was applied to graph Overall Survival (OS) and Progression-Free Survival (PFS). Results: Forty-seven patients were included. Twenty-one patients had disease limited to lungs, 9 to lung and liver, 7 only to liver, 10 to multiple sites. The median prescription SRT dose was 60 Gy per organ in 3 fractions (median biological effective dose of 180 Gy). The reduction of delta SUVmax (maximum Standardized Uptake Value) correlated with the local control (p<0.001) and two-years survival (p=0.003). At univariate analysis, localization of primary tumor, site of metastases, KRAS (Kirsten RAt Sarcoma) oncogene mutational status, response to first-line chemotherapy, response to SRT and number of treated lesions predicted both PFS and OS. Discussion: This real practice experience suggests that further studies are needed to analyze the promising role of SRT in the multidisciplinary management of mCRC.
KW - Chemotherapy
KW - Colorectal cancer
KW - Metastatic colorectal cancer
KW - Radiation therapy
UR - http://www.scopus.com/inward/record.url?scp=85055571556&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055571556&partnerID=8YFLogxK
M3 - Article
VL - 9
SP - 35251
EP - 35265
JO - Oncotarget
JF - Oncotarget
SN - 1949-2553
IS - 81
ER -